The placental passage of humulone and protopine was investigated with a human ex vivo placental perfusion model. The model was first validated with diazepam and citalopram, 2 compounds known to cross the placental barrier, and antipyrine as a positive control. All compounds were quantified by partially validated U(H)PLC-MS/MS bioanalytical methods. Only a small portion of humulone initially present in the maternal circuit reached the fetal circuit. The humulone concentration in the maternal circuit rapidly decreased, likely due to metabolization in the placenta. Protopine was transferred from the maternal to the fetal circuit, with a steady-state reached after 90 min. None of the study compounds affected placental viability or functionality, as glucose consumption, lactate production, beta-human chorionic gonadotropin, and leptin release remained constant. Histopathological evaluation of all placental specimens showed unremarkable, age-appropriate parenchymal maturation with no pathologic findings.

中文翻译：

---

体外人灌注系统中 Humulone 和 Protopine 的胎盘通道

用人类离体胎盘灌注模型研究了葎草酮和原素的胎盘通道。该模型首先用地西泮和西酞普兰（这两种已知可穿过胎盘屏障的化合物）和安替比林作为阳性对照进行了验证。所有化合物均通过部分验证的 U(H)PLC-MS/MS 生物分析方法进行量化。只有一小部分最初存在于母体回路中的葎草酮到达胎儿回路。母体回路中的葎草酮浓度迅速下降，可能是由于胎盘中的代谢。Protopine 从母体转移到胎儿回路，90 分钟后达到稳态。没有任何研究化合物影响胎盘活力或功能，如葡萄糖消耗、乳酸产生、β-人绒毛膜促性腺激素、瘦素的释放保持不变。所有胎盘标本的组织病理学评估显示无明显的、与年龄相适应的实质成熟，没有病理学发现。